Growth and expansion QPS Netherlands is part of a growing CRO with recent multi-site investments in the US and a broader 2024-2026 expansion trajectory, indicating potential for partnership in global clinical trials and expanded service scopes.

Clinical capabilities Full-suite CRO offerings from bioanalysis to clinical operations across Phase I–IV, with dedicated state-of-the-art bioanalytical labs, enabling end-to-end support for sponsor programs and opportunities to consolidate outsourcing.

Tech enablement Adoption of advanced tech such as LC-MS capabilities, OpenAI, LabVantage, and data analytics tooling supports efficient trial management, data handling, and accelerated decision-making—selling points for tech-forward sponsors.

Global reach Presence in the Netherlands with proximity to UMC Groningen and expansion into the United States (New Jersey, Delaware, Massachusetts) suggests a dual-focus model for multinational trials and simplified regulatory coordination.

Talent and capacity Headcount growth and key hires in cell therapy leadership alongside capacity expansion imply readiness to support specialized modalities and scalable staffing for growing project loads.